Free Trial

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos logo
$138.55 -4.70 (-3.28%)
(As of 11/14/2024 ET)

Glaukos - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
8

Based on 11 Wall Street analysts who have issued ratings for Glaukos in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for GKOS.

Consensus Price Target

$134.55
-2.89% Downside
According to the 11 analysts' twelve-month price targets for Glaukos, the average price target is $134.55. The highest price target for GKOS is $152.00, while the lowest price target for GKOS is $100.00. The average price target represents a forecasted downside of -2.89% from the current price of $138.55.
Get the Latest News and Ratings for GKOS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Glaukos and its competitors.

Sign Up

GKOS Analyst Ratings Over Time

TypeCurrent Forecast
11/16/23 to 11/15/24
1 Month Ago
10/17/23 to 10/16/24
3 Months Ago
8/18/23 to 8/17/24
1 Year Ago
11/16/22 to 11/16/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$134.55$130.45$127.73$81.22
Forecasted Upside-2.89% Downside1.76% Upside0.23% Upside25.35% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

GKOS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GKOS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Glaukos Stock vs. The Competition

TypeGlaukosMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-2.89% Downside26,222.18% Upside8.88% Upside
News Sentiment Rating
Positive News

See Recent GKOS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$130.00 ➝ $145.00+11.97%
11/5/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$135.00 ➝ $145.00+14.76%
10/17/2024Piper Sandler
2 of 5 stars
Matt O'Brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$140.00+5.29%
10/14/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$145.00 ➝ $152.00+18.87%
9/3/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$130.00 ➝ $145.00+8.30%
8/28/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$131.00 ➝ $139.00+2.93%
8/1/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$131.00 ➝ $137.00+16.91%
7/15/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$100.00 ➝ $120.00-1.70%
7/10/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$130.00 ➝ $132.00+8.50%
5/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$84.00 ➝ $125.00+17.36%
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $100.00+0.29%
5/4/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
12/28/2022Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$69.00 ➝ $68.00+66.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:37 AM ET.


GKOS Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Glaukos is $134.55, with a high forecast of $152.00 and a low forecast of $100.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GKOS shares.

According to analysts, Glaukos's stock has a predicted downside of -2.89% based on their 12-month stock forecasts.

Glaukos has been rated by research analysts at BTIG Research, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like Glaukos less than other "medical" companies. The consensus rating score for Glaukos is 2.73 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GKOS compares to other companies.


This page (NYSE:GKOS) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners